查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1995340

疫苗管瓶市場：按類型、材質、容量和瓶頸形式分類－2026-2032年全球市場預測

Vaccine Vials Market by Type, Material, Capacity, Neck Finish - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，疫苗管瓶市場價值將達到 7.7579 億美元，到 2026 年將成長至 8.6527 億美元，到 2032 年將達到 17.2683 億美元，年複合成長率為 12.10%。

主要市場統計數據
基準年 2025 7.7579億美元
預計年份：2026年 8.6527億美元
預測年份：2032年 1,726,830,000 美元
複合年成長率 (%) 12.10%

疫苗管瓶市場正經歷快速變革時期，其驅動力包括技術創新、不斷變化的監管要求以及地緣政治因素對醫療供應鏈日益成長的影響。這些因素正在重塑製造商、合約填充商、供應商和衛生監管機構評估材料選擇、生產基地選址和風險緩解策略的方式。如今，相關人員必須將傳統做法與聚合物設計、玻璃配方和無菌填充技術的快速發展相協調，同時也要應對多規格產品線營運的複雜性。

本導言探討了變革的關鍵促進因素，包括材料替代性、需求波動下的生產力計畫，以及貿易政策作為採購決策策略因素的日益重要。此外，本導言也重點介紹了擴大無菌生產規模所面臨的實際挑戰，例如驗證計畫、品管系統以及高等級生物安全灌裝線的資本密集度。後續章節將這些趨勢總結為實用見解，為必須在短期營運連續性和長期策略韌性之間取得平衡的決策者提供簡潔扼要的指南。

在技​​術創新和政策轉變的驅動下，變革性的變化正在重建疫苗管瓶生產、法律規範和供應鏈的韌性。

產業相關人員正見證著一場變革性的轉變，這場轉變超越了簡單的製程改進，涵蓋了管瓶設計、採購和監管的根本性變革。聚合物化學和阻隔性塑膠技術的進步提高了某些注射藥物非玻璃包裝方案的可行性，促使人們重新評估傳統上佔據主導地位的I型、II型和III型玻璃管瓶在某些應用情境下的優勢。同時，自動化無菌填充和整合檢測系統減少了生產線上的人工接觸，縮短了品質放行前置作業時間，並降低了污染風險。反過來，這也影響包裝材料的選擇和生產線佈局。

2025 年美國提案關稅對管瓶製造成本、籌資策略和跨境供應鏈設計的累積影響分析。

預計2025年實施的關稅措施將對管瓶生態系統內的採購經濟和策略規劃施加多方面的限制。這些措施不僅會影響到貨成本，還會影響供應商認證的速度以及有關本地生產的投資決策。如果關稅增加初級進口包裝的成本，決策者將面臨權衡：是自行承擔增加的採購成本，還是將其轉嫁給客戶，抑或是加快用於建立和擴大國內生產能力的資本投資。

關鍵細分洞察揭示了管瓶類型、材料成分、容量範圍和瓶頸端面選擇如何影響製造複雜性和採用趨勢。

市場細分為對整個管瓶市場的可操作性觀點，突顯了產品的複雜性、監管監管以及生產風險的集中程度。依產品類型分類，市場分為「多劑量」和「單劑量」製劑。這種區分對於填充和封蓋策略、防腐劑的相容性以及包裝線的更換頻率至關重要。多劑量製劑引發了人們對防腐劑在反覆開啟過程中的有效性和完整性的擔憂，而單劑量製劑則優先考慮最大限度地減少萃取物和減少過量灌裝，以確保劑量準確性。依材料分類，市場分為塑膠、I型玻璃、II型玻璃和III型玻璃。塑膠進一步細分為環烯烴聚合物和聚對苯二甲酸乙二醇酯，突顯了它們在阻隔性能、生技藥品和滅菌耐受性方面的差異。環烯烴聚合物具有低萃取物和優異的尺寸穩定性，使其適用於高度敏感的生技藥品。另一方面，聚對苯二甲酸乙二醇酯在某些疫苗配方中具有成本和生產效率的優勢。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和戰略定位：重點關注需求促進因素和製造地

每個地區都有其獨特的管理體制、製造生態系統和物流實際情況，因此區域趨勢會影響製造商、供應商和買家的策略選擇。美洲擁有主要的需求中心和高度無菌的填充能力，通常輔以嚴格的法律規範和眾多支持快速規模化的契約製造組織 (CMO)。該地區的採購決策受到支付方趨勢和公共衛生疫苗接種策略的影響，這些因素決定了是優先考慮單劑疫苗的便利性還是多劑疫苗的經濟性。

競爭格局分析，重點在於主要管瓶生產商的能力、產業重組趨勢、創新投資和夥伴關係模式。

管瓶產業的企業策略主要圍繞著幾個核心優先事項：確保品質和符合法規要求、擴大產能，以及透過材料創新和服務整合實現差異化。主要企業正在投資自動化、線上檢測和數位化品管系統，以縮短批次放行時間，並提高複雜價值鏈的可追溯性。其他企業則致力於垂直整合，進軍玻璃加工和聚合物複合領域，以控制利潤率並加速新型容器材料的認證。

為行業領導者提供實用建議，以最佳化韌性、投資靈活製造，並使商業化適應監管和貿易現實。

行業領導者應採取多管齊下的行動計劃，在應對迫在眉睫的風險的同時，建立長期的組織韌性。首先，加快供應商認證通訊協定，將替代材料和區域供應商納入其中，並將預測關稅和物流中斷的情境測試納入採購決策模型。其次，投資建造靈活的模組化無塵室設施和自動化設備，以實現快速的產品形態變化，並減少對勞力密集作業的依賴。第三，加強材料表徵程序，並記錄從原料到成品管瓶的可追溯性，以滿足日益嚴格的萃取物、浸出液和容器/密封系統完整性監管要求。

透明的調查方法，解釋了所使用的資料來源、專家訪談、供應鏈映射和檢驗方法，以確保分析的嚴謹性。

本摘要採用定性和定量相結合的分析方法，以確保其穩健性和有效性。主要研究包括對製造業企業高階主管、採購經理和監管專家進行結構化訪談，以了解實際營運和短期優先事項。除訪談外，還對材料安全文件、監管指南以及與無菌生產和容器/密封件測試相關的公開文件進行了技術審查。供應鏈圖譜追蹤了關鍵原料的流動，並識別出增加系統性風險的集中點。

此概要涉及整合法規、材料、生產能力和區域因素，以建構一個策略敘事，指南相關人員做出短期決策。

最終的綜合分析結合了材料科學、製造經濟學、監管預期和區域趨勢，建構了一個連貫的敘事框架，為可操作的決策提供指導。材料選擇仍然是決定產品性能和監管負擔的核心因素，玻璃和先進聚合物之間的權衡會影響生物製藥相容性、滅菌管道和永續性指標。透過投資自動化和模組化無塵室來提升製造柔軟性，將決定企業能否快速應對需求激增和政策衝擊。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：疫苗管瓶市場：依類型分類

  • 多次給藥
  • 單一劑量

第9章：疫苗管瓶市場：依材料分類

  • 塑膠
    • 環烯烴聚合物
    • 聚對苯二甲酸乙二酯
  • I型玻璃
  • II 型玻璃
  • 第三型玻璃

第10章：疫苗管瓶市場：依產能分類

  • 10ml
  • 2ml
  • 20ml
  • 5ml

第11章：疫苗管瓶市場：以瓶頸端型分類

  • 卷邊
  • 擰緊

第12章：疫苗管瓶市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：疫苗管瓶市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：疫苗管瓶市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國疫苗管瓶市場

第16章：中國疫苗管瓶市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Ardagh Group SA
  • Bormioli Pharma SpA
  • Corning Incorporated
  • Gerresheimer AG
  • Nipro Corporation
  • SCHOTT AG
  • SGD Pharma SA
  • Shandong Pharmaceutical Glass Co., Ltd.
  • Stevanato Group SpA
  • Vitro, SAB de CV
Product Code: MRR-F74E250AD5FF

The Vaccine Vials Market was valued at USD 775.79 million in 2025 and is projected to grow to USD 865.27 million in 2026, with a CAGR of 12.10%, reaching USD 1,726.83 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 775.79 million
Estimated Year [2026] USD 865.27 million
Forecast Year [2032] USD 1,726.83 million
CAGR (%) 12.10%

The vaccine vial landscape has entered a period of accelerated transformation driven by technological innovation, evolving regulatory requirements, and heightened geopolitical attention to medical supply chains. These forces are reshaping how manufacturers, contract packagers, suppliers, and health authorities assess material choices, production footprints, and risk mitigation strategies. Stakeholders must now reconcile legacy practices with rapid advances in polymer design, glass formulation, and aseptic filling technologies while managing the operational complexity of multi-format product lines.

This introduction frames the key vectors of change: material substitution possibilities, capacity planning under variable demand profiles, and the emergence of trade policy as a strategic factor in sourcing decisions. It also underscores the practical realities of scaling sterile manufacturing, such as validation timelines, quality management systems, and the capital intensity of high-containment filling lines. The following sections synthesize these dynamics into actionable insights, offering a concise orientation for decision-makers who must balance short-term operational continuity with longer-term strategic resilience.

Transformative shifts reshaping vaccine vial production, regulatory oversight, and supply chain resilience driven by technological innovation and policy changes

Industry participants are witnessing transformative shifts that extend beyond incremental process improvements to fundamental changes in how vials are designed, sourced, and regulated. Advances in polymer chemistry and high-barrier plastic technologies have elevated the viability of non-glass solutions for certain injectables, prompting reconsideration of traditional Type I, II, and III glass dominance in some use cases. Simultaneously, automated aseptic filling and integrated inspection systems are reducing human touchpoints on the line, shortening turnaround for quality release and lowering contamination risk, which in turn affects packaging selection and line layout.

Regulatory authorities are reinforcing focus on extractables and leachables, container closure integrity, and supply chain transparency, requiring manufacturers to provide deeper material characterization and provenance data. Trade policy and national security considerations have introduced new imperatives for regional supply capability, motivating investments in nearshore manufacturing and dual-sourcing strategies. These shifts are producing higher expectations for vendor traceability, accelerated qualification of alternative materials, and expanded collaboration between material suppliers and filling partners to co-develop validated solutions that meet both regulatory and operational criteria. In sum, the landscape is transitioning from a transactional buyer-supplier model to a collaborative, risk-managed ecosystem where cross-functional alignment is essential.

Cumulative impact analysis of proposed United States tariffs in 2025 on vial manufacturing costs, sourcing strategies, and cross-border supply chain design

Anticipated tariff actions in 2025 introduce a multi-dimensional constraint on sourcing economics and strategic planning for the vial ecosystem. Tariff measures affect not only landed cost but also the cadence of supplier qualification and the calculus of localized manufacturing investments. Where tariffs raise the cost of imported primary packaging, decision-makers face trade-offs between absorbing higher procurement costs, passing them through to customers, or accelerating capital deployment to establish or expand domestic production capacity.

The cumulative impact manifests across procurement cycle times, inventory policies, and supplier relationships. Organizations with lean inventory posture will feel near-term pressure to re-evaluate safety stock levels and to negotiate longer-term commitments with qualified suppliers to secure continuity. Conversely, firms with flexible manufacturing platforms and modular cleanroom designs can pivot more rapidly to alternate materials or localized suppliers, thereby mitigating tariff exposure. Strategic procurement teams will increasingly layer scenario planning into supplier scorecards, applying sensitivity analysis to tariff scenarios to guide capacity investments and contract terms. Ultimately, tariff-driven dynamics reinforce the value of diversified sourcing, investment in supplier development, and early engagement with regulators to ensure that any material or manufacturer changes remain compliant and auditable.

Key segmentation insights revealing how vial type, material composition, capacity ranges, and neck finish choices drive manufacturing complexity and adoption trends

Segmentation offers a practical lens to understand where product complexity, regulatory scrutiny, and manufacturing risk concentrate across the vial landscape. Based on Type, market is studied across Multi Dose and Single Dose, a distinction that matters for fill-finish strategy, preservative compatibility, and packaging line changeover frequency. Multi-dose formats drive concerns around preservative efficacy and repeated access integrity, while single-dose formats prioritize minimal extractables and lower overfill to support dosing accuracy. Based on Material, market is studied across Plastic, Type I Glass, Type II Glass, and Type III Glass. The Plastic is further studied across Cyclo Olefin Polymer and Polyethylene Terephthalate, a subdivision that highlights differences in barrier performance, compatibility with biologics, and sterilization resilience. Cyclo olefin polymers bring low extractables and excellent dimensional stability, making them attractive for sensitive biologics, whereas polyethylene terephthalate offers cost and throughput advantages for certain vaccine formulations.

Based on Capacity, market is studied across 10 Ml, 2 Ml, 20 Ml, and 5 Ml, a range that reflects clinical and programmatic dosing strategies and influences vial dimensions, neck finish requirements, and handling ergonomics on high-speed lines. Smaller capacities increase format proliferation and demand tighter tolerance control, whereas larger volumes reduce unit handling but require robust overfill controls and container closure integrity testing. Based on Neck Finish, market is studied across Crimp and Screw, which determines closure systems, sealing equipment, and compatibility with automated capping or crimping stations. Crimp finishes dominate traditional sterile parenteral supply chains because of proven hermetic seals with aluminum caps and rubber stoppers, while screw finishes enable faster assembly in some low-sterility settings and different sealing paradigms. Together, these segmentation vectors create a matrix of product and process decisions that influence design for manufacturability, regulatory submission content, and supplier selection criteria.

Regional dynamics and strategic positioning across Americas, Europe Middle East and Africa, and Asia-Pacific highlighting demand drivers and manufacturing hubs

Regional dynamics shape strategic choices for manufacturers, suppliers, and purchasers because each geography combines distinct regulatory regimes, manufacturing ecosystems, and logistics realities. Americas hosts significant demand centers and advanced aseptic filling capacity, often paired with stringent regulatory oversight and a large base of contract manufacturing organizations that support rapid scale-up. Its procurement decisions are influenced by payer dynamics and public health vaccination strategies, which in turn affect preferences for single-dose convenience versus multi-dose economy.

Europe, Middle East & Africa presents a heterogeneous landscape in which regulatory harmonization across the European Union coexists with capacity constraints and distribution challenges in several countries. Manufacturers in this region contend with high expectations for material characterization and environmental compliance while also navigating complex cross-border logistics across multiple jurisdictions. Asia-Pacific combines both large-scale manufacturing hubs and rapidly expanding domestic demand centers, supported by lower-cost production capabilities and a growing base of material suppliers offering glass and polymer solutions. Investment patterns here frequently favor high-volume production and vertical integration to capture efficiencies. Across all regions, proximity to end markets, customs regimes, and trade policy interplay to determine whether companies prioritize nearshoring, regional distribution centers, or global sourcing models, with risk-averse organizations tending toward diversified regional footprints to minimize single-point failures.

Competitive landscape intelligence focusing on capabilities, consolidation trends, innovation investments, and partnership models among leading vial manufacturers

Company strategies in the vial sector coalesce around a few core priorities: securing quality and regulatory compliance, scaling productive capacity, and differentiating through material innovation or service integration. Leading manufacturers are investing in automation, inline inspection, and digital quality systems to reduce batch release times and to improve traceability across complex value chains. Others pursue vertical integration into glass processing or polymer compounding to control margins and to accelerate qualification of novel container materials.

Partnership models are increasingly important; collaborations between material suppliers, primary packaging manufacturers, and contract fillers enable co-development programs that shorten validation timelines and align packaging properties with specific biologic attributes. Consolidation activity, strategic alliances, and targeted M&A are shaping capability footprints, but many organizations still compete on service responsiveness and the depth of regulatory support they offer customers. As environmental sustainability becomes a procurement criterion, firms that can demonstrate lifecycle analysis and recycling pathways for both glass and plastic containers gain preferential consideration among institutional buyers and public health agencies. Ultimately, competitive advantage flows from the ability to deliver validated, regulatory-ready containers at the scale and speed demanded by vaccination programs while maintaining cost discipline and supply assurance.

Actionable recommendations for industry leaders to optimize resilience, invest in flexible manufacturing, and align commercialization with regulatory and trade realities

Industry leaders should adopt a multi-pronged action plan that addresses immediate risks while positioning their organizations for longer-term resilience. First, accelerate supplier qualification protocols to include alternative materials and regional sources, and integrate scenario testing for tariff and logistics disruptions into procurement decision models. Second, invest in flexible, modular cleanroom capacity and automation that allow rapid format changeover and reduce dependence on labor-intensive operations. Third, strengthen material characterization programs to meet heightened regulatory expectations for extractables, leachables, and container closure integrity, documenting traceability from raw material to finished vial.

Leaders must also deepen collaborative ties with contract manufacturers, material suppliers, and regulatory consultants to co-create validated solutions and to shorten time-to-market for format changes. Build cross-functional war rooms that bring procurement, quality, regulatory, and operations together to evaluate trade-offs and to coordinate risk mitigation. Finally, embed environmental and circularity considerations into packaging strategies by assessing reuse and recycling pathways for both glass and plastic, and by communicating sustainability metrics to buyers and regulators. These steps will reduce vulnerability to trade shocks, improve responsiveness to shifting demand profiles, and create competitive differentiation based on reliability and regulatory readiness.

Transparent research methodology describing data sources, expert interviews, supply chain mapping, and validation approaches used to ensure rigorous analysis

The analytical approach underpinning this summary combined qualitative and quantitative methods to ensure robustness and relevance. Primary research included structured interviews with manufacturing executives, procurement leaders, and regulatory experts to capture operational realities and near-term priorities. These interviews were complemented by technical reviews of material safety dossiers, regulatory guidance documents, and public filings related to aseptic manufacturing and container closure testing. Supply chain mapping exercises traced key raw material flows and identified concentration points that elevate systemic risk.

Secondary analysis leveraged industry-standard technical literature on glass formulations, polymer science, and aseptic filling best practices to validate observed trends. Findings were triangulated across sources to reduce bias and to ensure conclusions reflected convergent evidence rather than isolated perspectives. Peer review by domain experts and subject-matter validation against publicly available regulatory outcomes further strengthened the methodology. The research process emphasized transparency, reproducibility, and operational relevance, producing insights that are grounded in practitioner experience and supported by technical documentation.

Concluding synthesis that integrates regulatory, material, capacity, and regional factors into a strategic narrative for stakeholders to inform near-term decisions

The concluding synthesis integrates material science, manufacturing economics, regulatory expectations, and regional dynamics into a cohesive narrative that guides practical decision-making. Material selection remains a central determinant of product performance and regulatory burden, with trade-offs between glass and advanced polymers affecting compatibility with biologics, sterilization pathways, and sustainability metrics. Manufacturing flexibility, enabled by automation and modular cleanroom investments, will determine which organizations can respond quickly to both demand surges and policy shocks.

Regulatory scrutiny and trade policy are now strategic variables that shape sourcing and capacity decisions; organizations that proactively qualify alternatives, document material provenance, and cultivate regional supplier networks will reduce exposure to disruption. Finally, collaboration across the ecosystem-bringing together material scientists, contract fillers, procurement professionals, and regulators-will be essential to deliver validated, scalable solutions. This synthesis points to a practical horizon in which resilience, technical rigor, and strategic partnerships together form the basis for competitive advantage in the vaccine vial sector.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Vaccine Vials Market, by Type

  • 8.1. Multi Dose
  • 8.2. Single Dose

9. Vaccine Vials Market, by Material

  • 9.1. Plastic
    • 9.1.1. Cyclo Olefin Polymer
    • 9.1.2. Polyethylene Terephthalate
  • 9.2. Type I Glass
  • 9.3. Type II Glass
  • 9.4. Type III Glass

10. Vaccine Vials Market, by Capacity

  • 10.1. 10 Ml
  • 10.2. 2 Ml
  • 10.3. 20 Ml
  • 10.4. 5 Ml

11. Vaccine Vials Market, by Neck Finish

  • 11.1. Crimp
  • 11.2. Screw

12. Vaccine Vials Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Vaccine Vials Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Vaccine Vials Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Vaccine Vials Market

16. China Vaccine Vials Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Ardagh Group S.A.
  • 17.6. Bormioli Pharma S.p.A.
  • 17.7. Corning Incorporated
  • 17.8. Gerresheimer AG
  • 17.9. Nipro Corporation
  • 17.10. SCHOTT AG
  • 17.11. SGD Pharma S.A.
  • 17.12. Shandong Pharmaceutical Glass Co., Ltd.
  • 17.13. Stevanato Group S.p.A.
  • 17.14. Vitro, S.A.B. de C.V.

LIST OF FIGURES

  • FIGURE 1. GLOBAL VACCINE VIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VACCINE VIALS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL VACCINE VIALS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL VACCINE VIALS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL VACCINE VIALS MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VACCINE VIALS MARKET SIZE, BY CAPACITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VACCINE VIALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL VACCINE VIALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VACCINE VIALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES VACCINE VIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA VACCINE VIALS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL VACCINE VIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL VACCINE VIALS MARKET SIZE, BY MULTI DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL VACCINE VIALS MARKET SIZE, BY MULTI DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL VACCINE VIALS MARKET SIZE, BY MULTI DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL VACCINE VIALS MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL VACCINE VIALS MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL VACCINE VIALS MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL VACCINE VIALS MARKET SIZE, BY PLASTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL VACCINE VIALS MARKET SIZE, BY PLASTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL VACCINE VIALS MARKET SIZE, BY PLASTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL VACCINE VIALS MARKET SIZE, BY CYCLO OLEFIN POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL VACCINE VIALS MARKET SIZE, BY CYCLO OLEFIN POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL VACCINE VIALS MARKET SIZE, BY CYCLO OLEFIN POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL VACCINE VIALS MARKET SIZE, BY POLYETHYLENE TEREPHTHALATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL VACCINE VIALS MARKET SIZE, BY POLYETHYLENE TEREPHTHALATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL VACCINE VIALS MARKET SIZE, BY POLYETHYLENE TEREPHTHALATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL VACCINE VIALS MARKET SIZE, BY TYPE I GLASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VACCINE VIALS MARKET SIZE, BY TYPE I GLASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VACCINE VIALS MARKET SIZE, BY TYPE I GLASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VACCINE VIALS MARKET SIZE, BY TYPE II GLASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL VACCINE VIALS MARKET SIZE, BY TYPE II GLASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL VACCINE VIALS MARKET SIZE, BY TYPE II GLASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL VACCINE VIALS MARKET SIZE, BY TYPE III GLASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL VACCINE VIALS MARKET SIZE, BY TYPE III GLASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL VACCINE VIALS MARKET SIZE, BY TYPE III GLASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL VACCINE VIALS MARKET SIZE, BY 10 ML, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL VACCINE VIALS MARKET SIZE, BY 10 ML, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL VACCINE VIALS MARKET SIZE, BY 10 ML, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL VACCINE VIALS MARKET SIZE, BY 2 ML, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL VACCINE VIALS MARKET SIZE, BY 2 ML, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL VACCINE VIALS MARKET SIZE, BY 2 ML, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL VACCINE VIALS MARKET SIZE, BY 20 ML, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL VACCINE VIALS MARKET SIZE, BY 20 ML, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VACCINE VIALS MARKET SIZE, BY 20 ML, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VACCINE VIALS MARKET SIZE, BY 5 ML, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VACCINE VIALS MARKET SIZE, BY 5 ML, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL VACCINE VIALS MARKET SIZE, BY 5 ML, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL VACCINE VIALS MARKET SIZE, BY CRIMP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL VACCINE VIALS MARKET SIZE, BY CRIMP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL VACCINE VIALS MARKET SIZE, BY CRIMP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL VACCINE VIALS MARKET SIZE, BY SCREW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL VACCINE VIALS MARKET SIZE, BY SCREW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL VACCINE VIALS MARKET SIZE, BY SCREW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL VACCINE VIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS VACCINE VIALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA VACCINE VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA VACCINE VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA VACCINE VIALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE VACCINE VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST VACCINE VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA VACCINE VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC VACCINE VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL VACCINE VIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN VACCINE VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)
  • TABLE 105. GCC VACCINE VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GCC VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. GCC VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 108. GCC VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 109. GCC VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 110. GCC VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION VACCINE VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS VACCINE VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)
  • TABLE 123. G7 VACCINE VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. G7 VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. G7 VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 126. G7 VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 127. G7 VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 128. G7 VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)
  • TABLE 129. NATO VACCINE VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. NATO VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. NATO VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 132. NATO VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 133. NATO VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 134. NATO VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL VACCINE VIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES VACCINE VIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA VACCINE VIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA VACCINE VIALS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA VACCINE VIALS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA VACCINE VIALS MARKET SIZE, BY PLASTIC, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA VACCINE VIALS MARKET SIZE, BY CAPACITY, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA VACCINE VIALS MARKET SIZE, BY NECK FINISH, 2018-2032 (USD MILLION)